China’s chemical pharmaceutical industry has maintained a good momentum of growth in recent years. In 2009, the number of chemical pharmaceutical manufacturers reached 2,434, up 7.5% year-on-year; the total value of industrial output achieved RMB420.7 billion, rising 10.9% year-on-year; and the pharmaceutical operating income reached RMB424.3 billion, a year-on-year increase of 19.5%.

Regarding the product structure, China is a big producer of active pharmaceutical ingredients (API). As of August 2010, China had had 1,197 active pharmaceutical ingredient manufacturers, been capable of producing over 1,500 categories of active pharmaceutical ingredients, and ranked No.1 in the world in terms of the output of penicillin, vitamins and antipyretics & analgesics. Furthermore, China is also the world’s biggest exporter of active pharmaceutical ingredients, with the export volume approximating half of the domestic output of active ingredients. From the perspective of export value, active pharmaceutical ingredient accounted for 80% of China’s total pharmaceutical export value in 2009; finished dosage form mainly addresses domestic demand, and only covered 6% of China’s total pharmaceutical export value in 2009.
China has many chemical pharmaceutical manufacturers, and the whole industry features a low concentration rate in general. However, the segmented markets have a higher concentration rate affected by technology, raw materials source, policy and large R&D investment of chemical pharmaceutical industry. For example, China Pharmaceutical Group Limited, Shandong Luwei Pharmaceutical Co., Ltd., Northeast Pharmaceutical Group Co., Ltd. and North China Pharmaceutical Group Corp. totally held over 90% shares in the domestic vitamin market, while Zhejiang Medicine Co., Ltd. alone covered 50% shares of the global vitamin H market in 2009.

Based on the abundant statistics, the report not only underlines the overall operation including the current development, profitability, import & export and competitive layout of China’s chemical pharmaceutical industry and its sub-sectors, but also makes an in-depth analysis of the operation and development advantages of China’s ten leading active pharmaceutical ingredient manufacturers and ten finished dosage form companies.
Northeast Pharmaceutical Group Co., Ltd., Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd. are China’s major vitamin manufacturers, as well as the key vitamin suppliers in the world. In the meantime, they are also actively expanding to produce other categories of active pharmaceutical ingredients.

North China Pharmaceutical Group Corp (NCPC) and Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharm) are China’s important antibiotic production bases. NCPC tops in China in terms of penicillin capacity and output, but is transferring to cephalosporin antibiotics under the mounting pressure of overcapacity; Xinhua Pharm is the biggest antipyretics and analgesics producer and exporter in Asia.

Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Pharma) and Zhejiang Huahai Pharmaceutical Co., Ltd. (Huahai Pharma) are the most competitive producers of special active pharmaceutical ingredients in China, both specializing in the R&D and production of chemical pharmaceuticals in the fields like anti-cancer, cardiovascular and nerve center. Moreover, the two companies both maintain a close cooperation with foreign pharmaceutical giants. Hisun Pharma cooperates with Eli Lilly and Schering-Plough in R&D and outsourcing, while Huahai Pharma supplies special active pharmaceutical ingredients and manufactures some finished dosage forms for German Boehringer Ingelheim GmbH and Swiss NOVARTIS.

Shenzhen Hepalink Pharmaceutical Co., Ltd is the world’s largest producer and seller as well as China’s only U.S. FDA and EU CEP– certified producer of heparin sodium active pharmaceutical ingredients. It occupied 26.7% of the worldwide sales volume of heparin sodium of 23.6 trillion units in 2009. Tianjin Tianyao Pharmaceutical Co., Ltd. and Zhejiang Xianju Pharmaceutical Co., Ltd. are the world’s major cortical hormone active pharmaceutical ingredients suppliers, monopolizing the mainland Chinese dexamethasone market in the ratio of 7:3.
# Table of Contents

1. **Overview of Chemical Pharmaceutical Industry**
   - 1.1 Definition & Classification
   - 1.2 Industry Chain

2. **Development of Global Chemical Pharmaceutical Industry**
   - 2.1 Status Quo
   - 2.2 Market Supply & Demand
     - 2.2.1 Product Structure
     - 2.2.2 Regional Structure
   - 2.3 Major Countries and Regions
     - 2.3.1 North America
     - 2.3.2 Europe
     - 2.3.3 Japan
   - 2.4 Development Trend

3. **Development of China’s Chemical Pharmaceutical Industry**
   - 3.1 Status Quo
   - 3.2 Profitability
     - 3.2.1 Active Pharmaceutical Ingredient
     - 3.2.2 Finished Dosage Form
   - 3.3 Import & Export
     - 3.3.1 Active Pharmaceutical Ingredient
     - 3.3.2 Finished Dosage Form
   - 3.4 Competition Layout
   - 3.5 Development Trend

4. **China’s Chemical Pharmaceutical Market Segments**
   - 4.1 Vitamins
     - 4.1.1 Status Quo
     - 4.1.2 Competition Layout
     - 4.1.3 Import & Export
   - 4.2 Antibiotics
     - 4.2.1 Status Quo
     - 4.2.2 Competition Layout
     - 4.2.3 Import & Export
   - 4.3 Antipyretics and Analgesics
<table>
<thead>
<tr>
<th>4.3.1 Status Quo</th>
<th>5.2.1 Profile</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.3.2 Competition Layout</td>
<td>5.2.2 Operation</td>
</tr>
<tr>
<td>4.3.3 Import &amp; Export</td>
<td>5.3 Zhejiang Medicine Co., Ltd</td>
</tr>
<tr>
<td>4.4 Hormones</td>
<td>5.3.1 Profile</td>
</tr>
<tr>
<td>4.4.1 Status Quo</td>
<td>5.3.2 Operation</td>
</tr>
<tr>
<td>4.4.2 Competition Layout</td>
<td>5.3.3 Development Trend &amp; Advantages</td>
</tr>
<tr>
<td>4.4.3 Import &amp; Export</td>
<td>5.4 Zhejiang Hisun Pharmaceutical Co., Ltd</td>
</tr>
<tr>
<td>4.5 Anti-tumor</td>
<td>5.4.1 Profile</td>
</tr>
<tr>
<td>4.5.1 Status Quo</td>
<td>5.4.2 Operation</td>
</tr>
<tr>
<td>4.5.2 Competition Layout</td>
<td>5.4.3 Development Trend &amp; Advantages</td>
</tr>
<tr>
<td>4.6 Cardiovascular and Cerebrovascular</td>
<td>5.5 Zhejiang NHU Company Ltd</td>
</tr>
<tr>
<td>4.6.1 Status Quo</td>
<td>5.5.1 Profile</td>
</tr>
<tr>
<td>4.6.2 Competition Layout</td>
<td>5.5.2 Operation</td>
</tr>
<tr>
<td>5. Domestic Manufacturers of Active Pharmaceutical Ingredients</td>
<td>5.5.3 Development Trend &amp; Advantages</td>
</tr>
<tr>
<td>5.1 Northeast Pharmaceutical Group Co., Ltd</td>
<td>5.6 Shandong Xinhua Pharmaceutical Company Limited</td>
</tr>
<tr>
<td>5.1.1 Profile</td>
<td>5.6.1 Profile</td>
</tr>
<tr>
<td>5.1.2 Operation</td>
<td>5.6.2 Operation</td>
</tr>
<tr>
<td>5.1.3 Development Trend &amp; Advantages</td>
<td>5.6.3 Development Trend &amp; Advantages</td>
</tr>
<tr>
<td>5.2 North China Pharmaceutical Group Corp(NCPC)</td>
<td>5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd</td>
</tr>
<tr>
<td>5.2.1 Profile</td>
<td>5.7.1 Profile</td>
</tr>
<tr>
<td>Section</td>
<td>Company Name</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>--------------------------------------------------------</td>
</tr>
<tr>
<td>5.7.2 Operation</td>
<td></td>
</tr>
<tr>
<td>5.7.3 Development Trend &amp; Advantages</td>
<td></td>
</tr>
<tr>
<td>5.8 Zhejiang Xianju Pharmaceutical Co., Ltd</td>
<td></td>
</tr>
<tr>
<td>5.8.1 Profile</td>
<td></td>
</tr>
<tr>
<td>5.8.2 Operation</td>
<td></td>
</tr>
<tr>
<td>5.8.3 Development Trend&amp; Advantages</td>
<td></td>
</tr>
<tr>
<td>5.9 Zhejiang Huahai Pharmaceutical Co., Ltd</td>
<td></td>
</tr>
<tr>
<td>5.9.1 Profile</td>
<td></td>
</tr>
<tr>
<td>5.9.2 Operation</td>
<td></td>
</tr>
<tr>
<td>5.9.3 Development Trend &amp; Advantages</td>
<td></td>
</tr>
<tr>
<td>5.10 Tianjin Tianyao Pharmaceutical Co., Ltd</td>
<td></td>
</tr>
<tr>
<td>5.10.1 Profile</td>
<td></td>
</tr>
<tr>
<td>5.10.2 Operation</td>
<td></td>
</tr>
<tr>
<td>5.10.3 Development Trend &amp; Advantages</td>
<td></td>
</tr>
<tr>
<td>6. Domestic Manufacturers of Finished Dosage Form</td>
<td></td>
</tr>
<tr>
<td>6.1 Beijing Double-Crane Pharmaceutical Co., Ltd</td>
<td></td>
</tr>
<tr>
<td>6.1.1 Profile</td>
<td></td>
</tr>
<tr>
<td>6.1.2 Operation</td>
<td></td>
</tr>
<tr>
<td>6.1.3 Development Trend</td>
<td></td>
</tr>
<tr>
<td>6.2 Jiangsu Hengrui Medicine Co., Ltd</td>
<td></td>
</tr>
<tr>
<td>6.2.1 Profile</td>
<td></td>
</tr>
<tr>
<td>6.2.2 Operation</td>
<td></td>
</tr>
<tr>
<td>6.2.3 Development Trend</td>
<td></td>
</tr>
<tr>
<td>6.3 Harbin Pharm. Group Sanjing Pharmaceutical Co., Ltd</td>
<td></td>
</tr>
<tr>
<td>6.3.1 Profile</td>
<td></td>
</tr>
<tr>
<td>6.3.2 Operation</td>
<td></td>
</tr>
<tr>
<td>6.3.3 Development Trend</td>
<td></td>
</tr>
<tr>
<td>6.4 Guangzhou Baiyunshan Pharmaceutical Co., Ltd</td>
<td></td>
</tr>
<tr>
<td>6.4.1 Profile</td>
<td></td>
</tr>
<tr>
<td>6.4.2 Operation</td>
<td></td>
</tr>
<tr>
<td>6.4.3 Development Trend</td>
<td></td>
</tr>
<tr>
<td>6.5 Livzon Pharmaceutical Group Inc.</td>
<td></td>
</tr>
<tr>
<td>6.5.1 Profile</td>
<td></td>
</tr>
<tr>
<td>6.5.2 Operation</td>
<td></td>
</tr>
<tr>
<td>6.5.3 Development Trend</td>
<td></td>
</tr>
<tr>
<td>6.6 Shanghai Fosun Pharmaceutical (Group) Co., Ltd</td>
<td></td>
</tr>
<tr>
<td>6.6.1 Profile</td>
<td></td>
</tr>
<tr>
<td>6.6.2 Operation</td>
<td></td>
</tr>
<tr>
<td>6.6.3 Development Trend</td>
<td></td>
</tr>
<tr>
<td>6.7 Chongqing Huapont Pharm. Co., Ltd</td>
<td></td>
</tr>
</tbody>
</table>
6.7.1 Profile
6.7.2 Operation
6.7.3 Development Trend
6.8 Hainan Haiyao Co., Ltd
6.8.1 Profile
6.8.2 Operation
6.8.3 Development Trend
6.9 Jiangsu Nhwa Pharmaceutical Co., Ltd
6.9.1 Profile
6.9.2 Operation
6.9.3 Development Trend
6.10 Huadong Medicine Co., Ltd
6.10.1 Profile
6.10.2 Operation
6.10.3 Development Trend
Selected Charts

- China’s Chemical Pharmaceutical Industry Segments
- Chemical Pharmaceutical Industry Value-added Chain
- Global Pharmaceutical Sales Revenue and Growth Rate, 2002-2009
- New Medicine Launched Worldwide, 2000-2009
- Global Generic Medicines (by Sales Revenue), 2003-2009
- Sales Revenue of Blockbuster Chemical Pharmaceutical Products in the World, 2009
- Global Medicine Sales Revenue (by Region), 2009
- Global Generic Medicine Sales Revenue (by Region), 2009
- Proportion of Health Care Spending to GDP in USA and Canada, 1970-2007
- Sales Revenue and Growth Rate of Medicine in North America, 2007-2009
- Proportion of Generic Medicine in the U.S. Pharmaceutical Market by Sales Volume and Revenue, 2000-2008
- Proportion of Health Care Spending to GDP in Germany and UK, 1970-2007
- Sales Revenue and Growth Rate of Medicine in Europe, 2007-2009
- Proportion of Health Care Spending to GDP in Japan, 1970-2007
- Sales Revenue and Growth Rate of Medicine in Japan, 2007-2009
- Average Annual Growth Rate of Global Pharmaceutical Market by Region, 2010-2014
- Number of Chemical Pharmaceutical Enterprises in China, 2006-May 2010
- Industrial Output Value and Sales Revenue of China’s Chemical Pharmaceutical Industry, 2006-2009
- Proportion of Chemical Pharmaceutical Industrial Output Value to GDP in China, 2005-2009
• Industrial Output Value of API And Finished Dosage Form in China, 2006-2009
• Prime Operating Revenue and Total Profit of China’s API Industry, 2006-May 2010
• Gross Margin and Sales Profit Margin of China’s API Industry, 2006-May 2010
• Prime Operating Revenue and Total Profit of China’s Finished Dosage Form Industry, 2006-May 2010
• Gross Margin and Sales Profit Margin of China’s Finished Dosage Form Industry, 2006-May 2010
• China’s Export of Medicine (By Value), 2009
• API Export, 2009
• Top 10 Pharmaceutical Enterprises in China by Export, 2009
• Monthly Export Volume and Value of Chemical Medicine in Unmeasured Dose in China, 2009
• Overseas Market Distribution of Chemical Medicine in Unmeasured Dose in China, 2009 (by Value),
• Monthly Export Volume and Value of Chemical Medicine in Measured Dose in China, 2009
• Overseas Market Distribution of Chemical Medicine in Measured Dose in China, 2009 (by Value),
• Monthly Import Volume and Value of Chemical Medicine in Unmeasured Dose in China, 2009
• Importing Countries of Chemical Medicine in Unmeasured Dose in China (by Value), 2009
• Monthly Import Volume and Value of Chemical Medicine in Measured Dose in China, 2009
• Importing Countries of Chemical Medicine in Measured Dose in China (by Value), 2009
• Segment Market Shares of Medicine Procured by Chinese Hospitals, 2009 (by Usage)
• China’s Health Care Expenditure and Proportion of Health Care Expenditure to GDP, 2000-2009
• Structure and Proportion of Health Care Expenditure in China, 2000-2008
• Proportion of Health Care Expenditure to Total Consumption Expenditure of Urban and Rural Residents in China, 2005-2008
• Major Chemical Pharmaceutical Projects under Planning/Construction in China, 2009
• Population and Proportion of People Aged over 65 in China, 2001-2009
• Market Prices of Main Vitamin APIs in China, 2006-Sep 2010
• Major Vitamin Manufacturers and Capacity in China, 2009
• Export Volume and Value of Vitamin in China, Jan-Sep 2010
• Import Volume and Value of Vitamin in China, Jan-Sep 2010
• Output of Main Antibiotic API Products in China, 2009
• Output of Major Antibiotic Finished Dosage Form Products in China, 2009
• Major Antibiotic API Manufacturers and Capacity in China, 2009
• Import Volume and Value of Antibiotic API and Finished Dosage Form in China, 2006-Aug 2010
• Antibiotic API Export Volume and Value in China, 2006-Aug 2010
• Import & Export Volume and Value of Paracetamol in China, Jan-Sep 2010
• Import & Export Volume and Value of Dipyrone in China, Jan-Sep 2010
• Import & Export Volume and Value of Aspirin in China, Jan-Sep 2010
• Import & Export Volume and Value of Caffeine in China, Jan-Sep 2010
• Import & Export Volume and Value of Ibuprofen in China, Jan-Sep 2010
• Export Volume and Value of Major Steroid Hormone Products in China, 2009
• Global Antineoplastic Medicine Market Scale, 2003-2008
• Market shares of Major Antineoplastic Companies in China, 2007
• Prices of Cardiovascular Medicine Purchased by Chinese Hospitals, 2005-2009
• Western Cardiovascular Medicine (by Usage) in China, 2005-2009
• Market Shares of Western Cardiovascular and Cerebrovascular Medicine (by Enterprise) in China, 2007-2009
• Price and Proportion of Western Cardiovascular and Cerebrovascular Medicine (by Chemical Structure) Purchased by Chinese Hospitals, 2009
• Operating Revenue of North China Pharmaceutical (by Industry and Product), 2009
• Operating Revenue of Northeast Pharmaceutical (by Industry and Product), H1 2010
• Operating Revenue of North China Pharmaceutical (by Region), 2009
• Operating Revenue of Northeast Pharmaceutical (by Region), H1 2010
• Top 5 Clients of Northeast Pharmaceutical by Operating Revenue, 2009
• Operating Revenue of North China Pharmaceutical (by Industry and Product), 2009
• Operating Revenue of North China Pharmaceutical (by Industry and Product), H1 2010
• Operating Revenue of North China Pharmaceutical (by Region), 2009
• Top 5 Clients of North China Pharmaceutical by Operating Revenue, 2009
• Top 5 Clients of North China Pharmaceutical by Operating Revenue, H1 2010
• Operating Revenue of Zhejiang Medicine (by Industry and Product), 2009
• Operating Revenue of Zhejiang Medicine (by Industry and Product), H1 2010
• Operating Revenue of Zhejiang Medicine (by Region), 2009
• Operating Revenue of Zhejiang Medicine (by Region), H1 2010
• Prime Operating Revenue and Total Profit of Hisun, 2007-H1 2010
• Operating Profit Margin of Hisun, 2007-H1 2010
• Operating Revenue and Proportion of Self-made Medicine of Hisun, 2007-H1 2010
• DMF and COS Certification of Hisun, June 2010
• Operating Revenue of Hisun (by Product), 2007-H1 2010
• Hisun’s R&D Investment and Contribution to Sales Revenue of Parent Company, 2007-2009
• Operating Revenue of NHU (by Industry and Product), 2009
• Operating Revenue of NHU (by Industry and Product), H1 2010
• Operating Revenue of NHU (by Region), 2009
• Operating Revenue of NHU (by Region), H1 2010
• Top 5 Clients of NHU by Operating Revenue, 2009
• Top 5 Clients of NHU by Operating Revenue, H1 2010
• Operating Revenue of Xinhua Pharmaceutical (by Product), 2009
• Operating Revenue of Xinhua Pharmaceutical (by Product), 2010
• Top 5 Clients of Xinhua Pharmaceutical by Operating Revenue, 2009
• Top 5 Clients of Xinhua Pharmaceutical by Operating Revenue, H1 2010
• Domestic Market Shares of Main Products of Xinhua Pharmaceutical, 2009
• Operating Revenue and Net Profit of Hepalink, 2007-H1 2010
• Prime Operating Revenue of Hepalink (by Product), 2007- H1 2010
• Gross Margin of Hepalink (by Product), 2007-H1 2010
• Top 5 Clients of Hepalink by Sales Revenue, 2009-H1 2010
• Export Volume, Value and Average Prices of Major Heparin Enterprises in China, Jan-Sep 2009
• Hepalink’s Shares in Chinese and Global Markets, 2007-2009
• Global Demand for Heparin API and Global Supply of Hepalink, 2009
• Operating Revenue of Xianju Pharma (by Product), 2009
• Operating Revenue of Xianju Pharma (by Product), H1 2010
• Operating Revenue of Xianju Pharma (by Region), 2009
• Operating Revenue of Xianju Pharma (by Region), H1 2010
• Eleven Subsidiaries of Huahai Pharmaceuticals
• Prime Operating Revenue and Total Profit of Huahai Pharmaceuticals, 2007-H1 2010
• Prime Operating Revenue of Huahai Pharmaceuticals (by Product), 2007-H1 2010
- DMF and COS Certification of Huahai Pharmaceuticals, by Jun 2010
- Prime Operating Revenue of Huahai Pharmaceuticals (by Region), 2007-H1 2010
- Top 5 Clients of Huahai Pharmaceuticals by Operating Revenue, 2009
- Ten Billion / Year Export Finished Dosage Form Project of Huahai Pharmaceuticals
- API Output and Growth Rate of Tianyao Pharmaceutical, 2007-2009
- Operating Revenue of Tianyao Pharmaceutical (by Product), 2009
- Operating Revenue of Tianyao Pharmaceutical (by Product), H1 2010
- Operating Revenue of Tianyao Pharmaceutical (by Region), 2009
- Operating Revenue of Tianyao Pharmaceutical (by Region), H1 2010
- Prime Operating Revenue of Double-Crane Pharmaceutical (by Industry and Product), 2009
- Prime Operating Revenue of Double-Crane Pharmaceutical (by Industry and Product), H1 2010
- Prime Operating Revenue of Double-Crane Pharmaceutical (by Region), 2009
- Prime Operating Revenue of Double-Crane Pharmaceutical (by Region), H1 2010
- Operating Revenue of Jiangsu Hengrui Medicine (by Product), 2009
- Operating Revenue of Jiangsu Hengrui Medicine (by Product), H1 2010
- Operating Revenue of Jiangsu Hengrui Medicine (by Region), 2009
- Operating Revenue of Jiangsu Hengrui Medicine (by Region), H1 2010
- Operating Revenue of Sanjing Pharmaceutical (by Product), 2009
- Operating Revenue of Sanjing Pharmaceutical (by Product), H1 2010
- Operating Revenue of Sanjing Pharmaceutical (by Region), 2009
- Operating Revenue of Sanjing Pharmaceutical (by Region), H1 2010
- Operating Revenue of Baiyunshan Pharmaceutical (by Industry and Product), 2009
- Operating Revenue of Baiyunshan Pharmaceutical (by Industry and Product), H1 2010
- Operating Revenue of Baiyunshan Pharmaceutical (by Region), 2009
• Operating Revenue of Baiyunshan Pharmaceutical (by Region), H1 2010
• Operating Revenue of Livzon Pharmaceutical Group (by Industry), 2009
• Operating Revenue of Livzon Pharmaceutical Group (by Industry), H1 2010
• Operating Revenue of Livzon Pharmaceutical Group (by Region), 2009
• Operating Revenue of Livzon Pharmaceutical Group (by Region), 2010
• Operating Revenue of Fosun Pharmaceutical (by Product), 2008-H1 2010
• Operating Revenue and Operating Profit of Western Medicine of Fosun Pharmaceutical, 2008-H1 2010
• Operating Revenue of Huapont Pharm. (by Industry, Product and Region), 2009
• Operating Revenue of Huapont Pharm. (by Industry and Product), H1 2010
• Operating Revenue of Hainan Haiyao (by Industry and Product), 2009
• Operating Revenue of Hainan Haiyao (by Industry and Product), H1 2010
• Operating Revenue of Hainan Haiyao (by Region), 2009
• Operating Revenue of Hainan Haiyao (by Region), H1 2010
• Operating Revenue of Nhwa Pharmaceutical (by Industry and Product), 2009
• Operating Revenue of Nhwa Pharmaceutical (by Industry and Product), H1 2010
• Operating Revenue of API and Finished Dosage Form of Nhwa Pharmaceutical (by Region), 2009
• Operating Revenue of API and Finished Dosage Form of Nhwa Pharmaceutical (by Region), H1 2010
• Operating Revenue of Huadong Medicine (by Industry and Product), 2009
• Operating Revenue of Huadong Medicine (by Industry and Product), H1 2010
• Operating Revenue of Huadong Medicine (by Region), 2009
• Operating Revenue of Huadong Medicine (by Region), H1 2010
### How to Buy

<table>
<thead>
<tr>
<th>Product Details</th>
<th>How to Order</th>
</tr>
</thead>
<tbody>
<tr>
<td>Single user</td>
<td>By email: <a href="mailto:report@researchinchina.com">report@researchinchina.com</a></td>
</tr>
<tr>
<td>USD 2,200 File PDF</td>
<td>By fax: 86-10-82601570</td>
</tr>
<tr>
<td>Enterprisewide 3,300 PDF</td>
<td>By online: <a href="http://www.researchinchina.com">www.researchinchina.com</a></td>
</tr>
<tr>
<td>Publication date: Dec. 2010</td>
<td></td>
</tr>
</tbody>
</table>

For more information, call our office in Beijing, China:
Tel: 86-10-82600828
Website: www.researchinchina.com